Effects of Resistant Potato Starch on the Gut Microbiota
NCT ID: NCT05242913
Last Updated: 2022-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75 participants
INTERVENTIONAL
2019-10-30
2020-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on the Effects of Resistant Potato Starch on Gut Bacteria in Healthy Adults
NCT06949631
Effects of MSPrebiotic on Gut Health in the Elderly
NCT01977183
Effect of a Nutritional Supplement on Gut Microbiota in Adults
NCT06611215
Study to Evaluate the Tolerability of Prebiotics on the Microbiota
NCT02628652
Effect of MSPrebiotic on Gastrointestinal Function and Blood Glucose Levels
NCT03910153
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High Dose SolnulTM
7.0 g of Resistant Potato Starch administered daily for 4 weeks
Resistant Potato Starch
Unmodified potato starch containing \>60% resistant starch Type 2
Low Dose SolnulTM
3.5 g of Resistant Potato Starch (plus 3.5 g digestible corn starch for 7.0 g total carbohydrate) administered daily for 4 weeks
Resistant Potato Starch
Unmodified potato starch containing \>60% resistant starch Type 2
Placebo
7.0 g digestible corn starch administered daily for 4 weeks
Placebo
Fully digestible corn starch
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Resistant Potato Starch
Unmodified potato starch containing \>60% resistant starch Type 2
Placebo
Fully digestible corn starch
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
69 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MSP Starch Products Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony Beir, MD
Role: PRINCIPAL_INVESTIGATOR
Nutrasource Pharmaceutical and Nutraceutical Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nutrasource Pharmaceutical and Nutraceutical Services
Guelph, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Bush JR, Alfa MJ. Consumption of resistant potato starch produces changes in gut microbiota that correlate with improvements in abnormal bowel symptoms: a secondary analysis of a clinical trial. BMC Nutr. 2024 Nov 27;10(1):152. doi: 10.1186/s40795-024-00962-7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R10356
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.